Indo Amines Ltd Q2 FY26 Results – Chemical Symphony with 12% OPM, 31% PAT Jump & New Morpholine Buzz
1. At a Glance
Indo Amines Ltd (IAL) just dropped its Q2 FY26 numbers, and the results smell like a well-balanced chemical reaction — stable topline, expanding margins, and an award shelf that’s beginning to look like a trophy shop. With a market cap of ₹900 crore, the stock trades at ₹124, well below its 52-week high of ₹211, making it look like that underrated compound in the periodic table — ignored, but potent.
The stock P/E stands at 12.8x, compared to the industry average of 28.9x, giving it that “value play” badge chemical analysts love flashing at conferences. ROE at 19% and ROCE at 18.3% show that the management knows its acids from its bases. The latest quarter (Q2 FY26) clocked ₹277 crore in revenue and ₹18.1 crore in PAT, marking a 31% YoY surge in profit on a modest 2.9% rise in sales.
While the company’s recent Morpholine & Derivatives launch at the Dhule plant added aromatic excitement, the financial reaction was exothermic — margins warmed up to a 12% operating margin, and export mix stayed strong at 46%. The only dilution in this chemistry lab? The share price — down nearly 29% YoY, proof that sometimes Mr. Market needs a little lab work too.
2. Introduction
Imagine a fine chemicals company that quietly goes about exporting to 70+ countries, manufactures 70+ products, and gets felicitated with a Rasayan Udyog Shri Award — yet, the stock sulks in a corner like a topper ignored at the farewell party. Welcome to Indo Amines Ltd, India’s unsung specialty chemicals all-rounder.
Born in 1992, the company grew up mixing and matching molecules across fine, specialty, and performance chemicals, feeding industries as diverse as pharma, perfumery, agrochemicals, and even road construction (yes, even our highways might have Indo Amines’ footprint).
FY25 was the year of balance — revenues crossed ₹1,100 crore, profits touched ₹70 crore, and the company added another shiny subsidiary to its molecular family via the amalgamation of Pious Engineering Pvt Ltd.
And if that wasn’t enough, in April 2025, IAL spiced up the chemical scene with a Morpholine & Derivatives launch, targeting global pharma and industrial clients. Because why just sell amines, when you can also make Morpholine sound like the next Marvel villain?
3. Business Model – WTF Do They Even Do?
In simple desi English, Indo Amines is a full-stack chemical juggler. Its product portfolio reads like the syllabus of a chemistry major with insomnia. Here’s the fun breakdown:
Fine Chemicals: High-purity chemicals used in pharmaceuticals and research — the kind you can’t spell without a periodic table handy.
Specialty Chemicals: Tailor-made compounds for niche industrial applications — the Gucci section of their product lineup.
Performance Chemicals: These go into lubricants, coatings, and plastics — basically, they make everything around you glide, shine, or resist heat.
Perfumery Chemicals: From jasmine to industrial solvents, these are the invisible agents behind “fragrance + function.”
Active Pharmaceutical Ingredients (APIs): Because why should drug manufacturers have all the fun? Indo Amines sells them the base molecules to keep the pharma party going.
The company operates five manufacturing units spread across Baroda, Dhule, Mahad, Badlapur, and Dombivli East, with a combined capacity of 1.10 lakh MTPA — or as the company might say, “a chemical factory at every corner of the map.”
Customer base? From Coca-Cola fragrances to pharma formulations, Indo Amines is like that friend who’s friends with everyone — sometimes too friendly with petrochemical players, sometimes close to perfumers, and occasionally hanging out with road constructors.
4. Financials Overview
Let’s put the Q2 FY26 microscope to work. The latest Quarterly Results (Sep 2025) showed a modest topline but strong bottomline expansion. Here’s the table you need:
Metric
Latest Qtr (Sep’25)
YoY Qtr (Sep’24)
Prev Qtr (Jun’25)
YoY %
QoQ %
Revenue
₹277 Cr
₹269 Cr
₹288 Cr
+3.0%
-3.8%
EBITDA
₹32 Cr
₹24 Cr
₹31 Cr
+33.3%
+3.2%
PAT
₹18.1 Cr
₹14 Cr
₹29 Cr
+29.3%
-37.6%
EPS (₹)
2.49
1.95
3.97
+27.7%
-37.3%
Annualized EPS (₹2.49 × 4) = ₹9.96, which neatly aligns with the trailing EPS of ₹9.65 — chemistry and accounting both check out.
Commentary: While revenue grew mildly, the company flexed operational efficiency like a veteran chemist in a cost-cutting lab. The PAT growth was 31% YoY — a clean reaction, no impurities. The QoQ dip was due to normalization after a super-strong Q1, but margins expanded to 12%, showing that this compound doesn’t decompose easily under market pressure.
